While acknowledging the caveats of cross-trial comparisons, it can be stated that olaparib (and also bisphosphonates, with caution) is currently the only medication demonstrating an overall survival benefit after curative surgery and (neo)adjuvant therapy in HR+/HER2- breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.